253 related articles for article (PubMed ID: 31558904)
41. Fast thermal simulations and temperature optimization for hyperthermia treatment planning, including realistic 3D vessel networks.
Kok HP; van den Berg CA; Bel A; Crezee J
Med Phys; 2013 Oct; 40(10):103303. PubMed ID: 24089933
[TBL] [Abstract][Full Text] [Related]
42. Cell line-specific efficacy of thermoradiotherapy in human and canine cancer cells in vitro.
Nytko KJ; Thumser-Henner P; Weyland MS; Scheidegger S; Rohrer Bley C
PLoS One; 2019; 14(5):e0216744. PubMed ID: 31091255
[TBL] [Abstract][Full Text] [Related]
43. Clinical system for simultaneous external superficial microwave hyperthermia and cobalt-60 radiation.
Moros EG; Straube WL; Klein EE; Maurath J; Myerson RJ
Int J Hyperthermia; 1995; 11(1):11-26. PubMed ID: 7714365
[TBL] [Abstract][Full Text] [Related]
44. Applications of bioheat transfer simulations in hyperthermia.
Roemer RB; Cetas TC
Cancer Res; 1984 Oct; 44(10 Suppl):4788s-4798s. PubMed ID: 6467231
[TBL] [Abstract][Full Text] [Related]
45. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Horsman MR
Int J Hyperthermia; 2004 Jun; 20(4):393-404. PubMed ID: 15204520
[TBL] [Abstract][Full Text] [Related]
46. Radiotherapy with 8 MHz radiofrequency-capacitive regional hyperthermia for pain relief of unresectable and recurrent colorectal cancer.
Ohguri T; Imada H; Kato F; Yahara K; Morioka T; Nakano K; Korogi Y
Int J Hyperthermia; 2006 Feb; 22(1):1-14. PubMed ID: 16423749
[TBL] [Abstract][Full Text] [Related]
47. Thermoradiotherapy combined with p53 gene therapy of human salivary gland adenocarcinoma cell line.
Asaumi J; Higuchi Y; Murakami J; Matsuzaki H; Wakasa T; Inoue T; Shigehara H; Konouchi H; Hisatomi M; Kawasaki S; Kuroda M; Hiraki Y; Kishi K
Oncol Rep; 2003; 10(1):71-4. PubMed ID: 12469147
[TBL] [Abstract][Full Text] [Related]
48. Hyperthermia in oncology.
Falk MH; Issels RD
Int J Hyperthermia; 2001; 17(1):1-18. PubMed ID: 11212876
[TBL] [Abstract][Full Text] [Related]
49. RF hyperthermia array modelling; validation by means of measured EM-field distributions.
Wiersma J; Van Dijk JD
Int J Hyperthermia; 2001; 17(1):63-81. PubMed ID: 11212881
[TBL] [Abstract][Full Text] [Related]
50. Thermoradiotherapy for residual microscopic cancer: elective or post-excisional hyperthermia and radiation therapy in the management of local-regional recurrent breast cancer.
Kapp DS; Cox RS; Barnett TA; Ben-Yosef R
Int J Radiat Oncol Biol Phys; 1992; 24(2):261-77. PubMed ID: 1526865
[TBL] [Abstract][Full Text] [Related]
51. Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial.
Sherar M; Liu FF; Pintilie M; Levin W; Hunt J; Hill R; Hand J; Vernon C; van Rhoon G; van der Zee J; Gonzalez DG; van Dijk J; Whaley J; Machin D
Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):371-80. PubMed ID: 9308941
[TBL] [Abstract][Full Text] [Related]
52. [Standards and perspectives in locoregional hyperthermia].
Hildebrandt B; Rau B; Gellermann J; Kerner T; Nicolaou A; Blohmer JU; Trappe RU; Riess H; Wust P
Wien Med Wochenschr; 2004 Apr; 154(7-8):148-58. PubMed ID: 15182041
[TBL] [Abstract][Full Text] [Related]
53. [Clinical assessment of thermoradiotherapy of breast cancer and cancer of the urinary bladder].
Hiraoka M; Masunaga S; Nishimura Y; Nagata Y; Li YP; Koishi M; Mitsumori M; Abe M; Takahashi M; Akuta K
Gan No Rinsho; 1990 Oct; 36(13):2267-71. PubMed ID: 2250346
[TBL] [Abstract][Full Text] [Related]
54. Thermal dose-response of magnetic-induction thermoradiotherapy.
Storm FK; Elashoff RM; Baker HW; Scanlon EF; Drury B; Lee M; Roe D; Morton DL
J Surg Oncol; 1988 Oct; 39(2):79-83. PubMed ID: 3172795
[TBL] [Abstract][Full Text] [Related]
55. Multiple field hyperthermia combined with radiotherapy in advanced carcinoma of the breast.
Engin K; Tupchong L; Waterman FM; Komarnicky L; Mansfield CM; Hussain N; Hoh LL; McFarlane JD; Leeper DB
Int J Hyperthermia; 1994; 10(5):587-603. PubMed ID: 7806917
[TBL] [Abstract][Full Text] [Related]
56. Site-specific phase I, II trials of hyperthermia at Kyoto University.
Hiraoka M; Nishimura Y; Nagata Y; Mitsumori M; Okuno Y; Li PY; Abe M; Takahashi M; Masunaga S; Akuta K
Int J Hyperthermia; 1994; 10(3):403-10. PubMed ID: 7930807
[TBL] [Abstract][Full Text] [Related]
57. Predictive value of simulated SAR and temperature for changes in measured temperature after phase-amplitude steering during locoregional hyperthermia treatments.
Kok HP; Schooneveldt G; Bakker A; de Kroon-Oldenhof R; Korshuize-van Straten L; de Jong CE; Steggerda-Carvalho E; Geijsen ED; Stalpers LJA; Crezee J
Int J Hyperthermia; 2018; 35(1):330-339. PubMed ID: 30300028
[TBL] [Abstract][Full Text] [Related]
58. Change in expression of apoptosis genes after hyperthermia, chemotherapy and radiotherapy in human colon cancer transplanted into nude mice.
Liang H; Zhan HJ; Wang BG; Pan Y; Hao XS
World J Gastroenterol; 2007 Aug; 13(32):4365-71. PubMed ID: 17708613
[TBL] [Abstract][Full Text] [Related]
59. Clinical use of the hyperthermia treatment planning system HyperPlan to predict effectiveness and toxicity.
Sreenivasa G; Gellermann J; Rau B; Nadobny J; Schlag P; Deuflhard P; Felix R; Wust P
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):407-19. PubMed ID: 12527054
[TBL] [Abstract][Full Text] [Related]
60. Novel hyperthermia applicator system allows adaptive treatment planning: Preliminary clinical results in tumour-bearing animals.
Dressel S; Gosselin MC; Capstick MH; Carrasco E; Weyland MS; Scheidegger S; Neufeld E; Kuster N; Bodis S; Rohrer Bley C
Vet Comp Oncol; 2018 Jun; 16(2):202-213. PubMed ID: 28892246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
